Am J Transplant, Volume 18, Suppl 3 Archives - Page 181 of 211 - ATC Abstracts

2018 American Transplant Congress
Influence of Dendritic Cell Subsets on Enhancing Oral Tolerance in Cardiac Transplantation Model
G. Gu, T. Lu, N. Xu, Q. Xia.
Department of Liver Surgery, Renji Hospital, Affiliated by Shanghai Jiaotong University Medical School, Shanghai, China.
Oral tolerance has been implicated in the protection of transplant rejection in the animal models. Antigen presenting cells (APCs) are responsible for sampling their environment…
2018 American Transplant Congress
Pre-Transplant versus De Novo Donor Specific Antibodies: Differences in Clinical Outcomes and Antibody Mediated Rejection
M. Ajaimy, N. Hayde, A. Colovai, E. Akalin.
Montefiore-Einstein Transplant Center, Montefiore-Einstein Transplant Center, Bronx.
Background: Antibody mediated rejection (ABMR) can occur through pre-transplant(tx) vs. de novo donor specific antibodies (DSA). Clinical outcomes, allograft injury and dynamics of DSAs have…
2018 American Transplant Congress
Timing of Treatment for Chronic Hepatitis C Infection in Patients with End-Stage Renal Disease Awaiting Transplantation
M. Eckman,¹ E. Woodle,² C. Thakar,¹ F. Paterno,² K. Sherman.¹
¹Medicine, University of Cincinnati, Cincinnati, OH; ²Surgery, University of Cincinnati, Cincinnati, OH.
BackgroundIt is unclear whether patients with chronic hepatitis C virus (HCV) infection and end-stage renal disease (ESRD) should be treated for HCV before transplant or…
2018 American Transplant Congress
Time-Effect of Donor and Recipient Characteristics on Graft Survival after Kidney Transplantation
E. Molmenti,¹ J. Yang,³ C. Molmenti,² E. Grodstein,¹ H. Rilo,¹ L. Teperman.¹
¹Surgery, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY; ²Feinstein Institute, Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY; ³Epidemiology, Mailman Schoool of Public Health, Columbia University, New York, NY.
BackgroundThe current kidney allocation system (KAS) is based on the Kidney Donor Profile Index (KDPI) and the Estimated Post-Transplant Survival (EPTS), quality-based “longevity matching” strategies…
2018 American Transplant Congress
12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients
M. Matignon,¹ C. Dudreuilh,¹ P. Rémy,¹ J-.L. Taupin,² P. Grimbert.¹
¹Nephrology Transplantation, APHP Henri Mondor, Creteil, France; ²Histocompatibility, APHP Saint Louis, Paris, France.
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…
2018 American Transplant Congress
A Novel Combined Formula to Direct Optimal Immunosuppressive Drug Exposure in Renal Transplant Recipients
O. Pankewycz,¹ E. Onan,² M. Laftavi,¹ R. Gruessner,³ H. Smileuski,¹ E. Alissandrello,¹ A. Gruessner.³
¹Upstate Medical University, Syracuse, NY; ²Cukurova University, Adana, Turkey; ³Downstate Medical University, New York, NY.
Purpose: The most widely used maintenance immunosuppressive combination after kidney transplantation is tacrolimus (TAC) and mycophenolic acid (MPA). The utility of therapeutic drug monitoring for…
2018 American Transplant Congress
Target Tacrolimus Troughs and CYP3A5 Polymorphisms Do Not Predict Therapeutic Drug Exposure in African American and Caucasian Renal Transplant Recipients
K. Tornatore,^1,4 K. Attwood,² D. Brazeau,³ S. Chang,⁴ R. Venuto.⁴
¹Pharmacy, School of Pharmacy, University at Buffalo(UB), Buffalo; ²Biostatistics, RPCI, Buffalo; ³Pharmaceutical Sciences, University of New England, Portland; ⁴Nephrology, UB School of Medicine, Buffalo.
Background: African American(AA) renal transplant recipients(RTR) require larger tacrolimus(TAC) doses to achieve similar troughs to Caucasians which may be due to CYP3A5 polymorphisms. TAC pharmacokinetics…
2018 American Transplant Congress
Variation in Living Donor Kidney Transplantation among U.S. Transplant Centers
T. Melanson,¹ M. Basu,¹ L. Plantiga,¹ S. Pastan,¹ S. Mohan,² R. Patzer.¹
¹Emory University, Atlanta; ²Columbia University, New York.
Introduction: Living donor kidney transplant (LDKTx) is the preferred treatment for patients with end-stage renal disease (ESRD) but continues to be less common than deceased…
2018 American Transplant Congress
Cumulative Sum Analysis of the Learning Curve for Video-Assisted Minilaparotomy Donor Nephrectomy in Healthy Kidney Donors
J. Na,¹ J. Park,¹ M-.G. Yoon,¹ H. Lee,² Y. Yoon,³ K. Huh,⁴ M. Kim,⁴ S. Kim,⁴ Y. Kim,⁴ W. Han.¹
¹Department of Urology, Yonsei University College of Medicine, Urological Science Institute, Seoul, Korea; ²Department of Urology, National Health Insurance Service Ilsan Hospital, Goyang-si, Korea; ³Department of Urology, Hanyang University Medical Center, Seoul, Korea; ⁴Department of Surgery-Transplantation, Yonsei University College of Medicine, Seoul, Korea.
Background:Video-assisted minilaparotomy surgery (VAMS) is a hybrid of open and laparoscopic surgical techniques, so has advantages of both approaches. Here we examined the learning curve…
2018 American Transplant Congress
Temporal Trends in Living Kidney Donor Candidates
S. Singh,^1,2 V. DiCecco,² M. Luo,² Y. Li,² O. Famure.²
¹Division of Nephrology, Department of Medicine, University of Toronto, Toronto, ON, Canada; ²Division of Nephrology and the Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
Living kidney donor transplantation is the preferred treatment option for end-stage renal disease. However, living kidney donation rates have plateaued in North America. Existing studies…